Creative Biolabs helps researchers and developers identify, compare, and prioritize tumor indications for oncolytic virus programs by integrating tumor biology, viral tropism, immune microenvironment, biomarker readiness, model availability, delivery feasibility, and translational risk.
Selecting the right cancer indication is an early development decision that determines how an oncolytic virus program should be validated, positioned, and advanced. The goal is to identify tumor types where the viral platform, target biology, delivery route, model strategy, and translational rationale are aligned before major resources are committed.
Creative Biolabs provides a structured indication selection service that turns broad disease opportunities into a prioritized, evidence-supported roadmap. The assessment can support naturally tumor-selective viruses, engineered or armed OVs, retargeted platforms, and combination-oriented programs.
This section defines the problem. The detailed scoring criteria are handled later in the scorecard.
Creative Biolabs customizes the analysis according to the client's viral platform, payload design, target product profile, available data package, and development stage.
Evaluate tumor permissiveness, receptor or co-receptor expression, antiviral pathway status, architecture, stromal barriers, and known susceptibility to the selected OV platform.
Review immune infiltration, antigen presentation, interferon responsiveness, suppressive cell populations, checkpoint activity, and cytokine or chemokine features.
Assess local, regional, cavity-based, intracranial, intravesical, or systemic delivery together with repeat dosing, biodistribution, and off-target exposure.
Plan markers for viral entry, replication permissiveness, immune activation, payload expression, tumor burden, pharmacodynamic monitoring, and treatment response.
Balance disease burden, standard-of-care limitations, OV differentiation potential, combination opportunity, and positioning within the treatment landscape.
Match each indication with practical model systems for staged in vitro validation, 3D testing, in vivo efficacy, biodistribution, safety, and immune mechanism studies.
Review normal tissue tropism, pre-existing immunity, shedding concerns, payload toxicity, genetic stability, assay readiness, manufacturing complexity, and regulatory expectations.
This scope focuses on what Creative Biolabs can perform during an indication selection project, while the framework above explains how cancer opportunities are evaluated.
Collect and organize prior data, disease rationale, platform assumptions, and knowledge gaps into a usable assessment base.
Compare tumor opportunities using client-defined weights, disease priorities, and practical development objectives.
Determine whether the OV platform may require retargeting, detargeting, arming, route-specific support, or additional validation.
Evaluate practical options for local, regional, cavity-based, intracranial, intravesical, or systemic administration.
Define candidate markers for target engagement, viral replication, immune activation, payload expression, and response.
Recommend staged model systems for screening, confirmation, mechanism, efficacy, biodistribution, and safety studies.
Identify the main translational risks and the shortest study path for reducing uncertainty before deeper investment.
Deliver a prioritized indication roadmap with disease-specific next steps, validation triggers, and suggested follow-up studies.
Use this table as a scoring tool. Detailed scientific interpretation should be handled in the framework and final report, not repeated here.
| Evaluation Dimension | Key Question | Preferred Evidence | Score |
|---|---|---|---|
| Tumor Biology | Does the tumor support viral entry, replication, spread, and selectivity? | Receptor data, permissiveness data, antiviral pathway status, tumor architecture notes. | 1-5 |
| Viral Tropism Fit | Is the viral platform naturally or engineerably aligned with the indication? | Tropism rationale, retargeting need, off-target risk assessment. | 1-5 |
| Immune Microenvironment | Can the indication benefit from OV-mediated immune activation or combination therapy? | Immune infiltration, antigen presentation, checkpoint activity, interferon response data. | 1-5 |
| Delivery Feasibility | Can the intended route reach the disease site and support repeatable dosing? | Accessibility, route practicality, exposure and shedding considerations. | 1-5 |
| Biomarker Readiness | Are there measurable markers for patient selection and pharmacodynamic decisions? | Entry markers, replication assays, immune markers, payload and response readouts. | 1-5 |
| Clinical Unmet Need | Is there a compelling clinical and competitive rationale? | Treatment limitation, refractory setting, differentiation and combination opportunity. | 1-5 |
| Model Availability | Are practical models available for staged validation? | Cell panels, organoids, xenografts, syngeneic, PDX, orthotopic, or humanized models. | 1-5 |
| Translational Risk | Are safety, immune, shedding, payload, assay, and manufacturing risks manageable? | Risk summary, mitigation options, and recommended follow-up studies. | 1-5 |
Each step is kept decision-oriented so the workflow does not repeat the scope, framework, or deliverables sections.
Define viral platform, payload, route concept, candidate status, and selection goal.
Build a tumor indication list based on biology, clinical rationale, and client priorities.
Identify missing data that could affect platform fit, model choice, route feasibility, or risk.
Apply weighted scoring and separate high-priority, moderate-priority, and high-risk options.
Recommend focused experiments, model strategy, priority cancer directions, and next milestones.
Translate the roadmap into disease-focused study scope, validation sequence, and proposal-ready next steps.
Use this workflow for early platform positioning, first-indication selection, broad opportunity narrowing, or repositioning of an existing OV candidate.
Deliverables are written to support prioritization and next-step planning, not to repeat the full assessment framework.
These scenarios focus on project context. The technical criteria are covered in the framework and scorecard sections.
After a tumor indication has been shortlisted, use the pathways below to refine model strategy, delivery route, biomarkers, and validation plans. For broader browsing by tumor category, visit our oncolytic virotherapy by cancer type guide.
Creative Biolabs connects indication selection with practical downstream work, including engineering, construction, in vitro validation, animal model planning, efficacy studies, biodistribution analysis, immune profiling, and disease-specific development.
This integration helps clients move from a ranked indication list to executable validation studies with fewer handoff gaps.
Browse answers about timing, applicable OV platforms, starting information, experimental validation, and the role of disease-specific service pages.
Indication selection is most useful before major resources are committed to extensive engineering, animal efficacy studies, or IND-enabling planning. It can also be performed when repositioning an existing OV platform or comparing multiple tumor opportunities.
Yes. The framework can be adapted for naturally tumor-selective viruses, retargeted viruses, armed viruses, promoter-controlled viruses, detargeted viruses, and candidates intended for combination therapy.
Useful starting materials include the viral platform, engineering design, proposed payload, available infection or cytotoxicity data, intended route of administration, target product profile, preferred cancer types, and any existing model or biomarker data.
Yes. The strategic report can be extended into focused validation studies, such as tumor cell panel screening, receptor profiling, 3D or organoid testing, animal model selection, biodistribution analysis, or efficacy evaluation.
This page functions as a decision-making and prioritization service. Disease-specific pages should be used after the indication has been selected or shortlisted, when the client needs focused development support for a particular cancer type.
If you are evaluating which cancer indication best fits your oncolytic virus platform, Creative Biolabs can help build a data-supported roadmap. Contact us to discuss your viral platform, candidate design, disease priorities, and available data package.